drugset
drugset / Trial / NCT06060613

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

NCT06060613 ↗

Phase 1/2 Recruiting 208 enrolled Obsidian Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.

Timeline

Start
2023-10-25
Primary completion
2029-06-30
Completion
2029-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject OBX-115 Cell therapy — —

Indications

metastatic melanoma non-small cell lung carcinoma skin neoplasm